All Eyes On Bristol's New Launches
Bristol Myers Squibb has launched three new first-in-class drugs this year – Opdualag, Camzyos and Sotyktu – and investors are closely watching the early momentum.
You may also be interested in...
Bristol-Myers Squibb’s Abraxis Unit, Nephron and Lupin hit with warning letters; Lupin and Jubilant 483 inspection reports posted.
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.